Jason Luke
MD
Associate Professor and Director of Cancer Immunotherapeutics Center
👥Biography 个人简介
Jason Luke led KEYNOTE-716 establishing adjuvant pembrolizumab for high-risk stage IIB and IIC resected melanoma, expanding adjuvant IO indications to earlier stages. His work demonstrated significant recurrence-free survival benefit in patients historically observed without systemic therapy. He continues to refine risk-adapted adjuvant selection.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Jason Luke 的研究动态
Follow Jason Luke's research updates
留下邮箱，当我们发布与 Jason Luke（UPMC Hillman Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment